Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22929998 | 0.87 | GOT1 (0.34) | GOT1CYP1A2FFAR2 | |
| SCHEMBL17036640 | 0.81 | GOT1 (0.54) | GOT1FFAR2 | |
| SCHEMBL19852697 | 0.79 | IDH1 (0.36) | CYP1A2 | |
| SCHEMBL22328213 | 0.78 | RAB9A (0.38) | — | |
| SCHEMBL12883344 | 0.71 | CHRNB2 (0.41) | CYP1A2 | |
| SCHEMBL18160808 | 0.70 | NCF1 (0.36) | — | |
| SCHEMBL20436545 | 0.70 | HSD11B1 (0.40) | — | |
| SCHEMBL26441388 | 0.68 | NPSR1 (0.38) | — | |
| SCHEMBL13626475 | 0.67 | HSD11B1 (0.42) | — | |
| SCHEMBL25522581 | 0.65 | GOT1 (0.33) | GOT1FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | GOT1 51/4885CYP1A2 3563/4885FFAR2 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.